KALA Bio enters $375k convertible loan; Oxford pauses foreclosure, company faces cash crunch

KALA BIO, Inc.

Convertible loan of up to $375k from individual investor; first $187.5k due Nov 10, remainder by Nov 12, 2025.
Loan bears 15% simple interest; lender can convert into common stock at defined prices.
Proceeds limited to negotiating further investment with lender and preparing Q3 2025 Form 10-Q.
Oxford paused asset foreclosure on Nov 3. If no additional financing, foreclosure expected to resume.
Company cannot seek alternative offers from others until Nov 17, 2025; warns of going-concern risk.

item 1.01 item 2.03 item 3.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

KALA BIO, Inc. issued convertible note to individual investor for aggregate amount of up to $375,000.

Security: convertible note
Purchaser: individual investor
Consideration: aggregate amount of up to $375,000

Exact text from the filing

On November 9, 2025 (the “Execution Date”), KALA Bio, Inc. (the “Company”) entered into a Convertible Loan Agreement (the “Loan Agreement”) with an individual investor (the “Lender”), pursuant to which the Lender agreed to provide the Company a convertible loan in the aggregate amount of up to $375,000

View on SEC.gov

17 equity issuances filed in the last 30 days. Browse all equity issuances →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-108844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.